Menin inhibitors for infant KMT2A-rearranged ALL
Infant leukaemia is driven almost entirely by KMT2A fusions, which menin inhibitors were built to attack. Add them to the new blinatumomab-containing backbone.
Infant ALL EFS plateaued below 50% for two decades; blinatumomab (Interfant-21) is the first step forward. Revumenib is approved for KMT2Ar acute leukaemia including children ≥1 year and has paediatric formulation data; combining with chemotherapy and blinatumomab in the first year of life is the obvious next trial.
Pages like this
not linked directly; found by shared links- Key paperAUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation
Shares AUGMENT-101, KMT2A (MLL) rearrangement, Ziftomenib, Revumenib.
- PairingMenin inhibitor + venetoclax + azacitidine
Shares KMT2A (MLL) rearrangement, Ziftomenib, Revumenib, Menin.
- TargetNPM1 mutation
Shares AUGMENT-101, Ziftomenib, Revumenib, Menin.
- TermDifferentiation syndrome
Shares AUGMENT-101, Ziftomenib, Revumenib, Menin.
- TrialKOMET-001
Shares Ziftomenib, Menin.
- InstitutionSIOP Europe – European Society for Paediatric Oncology
Shares Interfant-06, Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
- PersonEunice S. Wang
- TrialCOG AALL1731
Shares Blinatumomab, Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.